Thanks for emailing that article!
Speeding the Development of New Glaucoma Therapies.
Clinicians, entrepreneurs, and leaders from the FDA, finance, and industry will gather for the 5th Annual Glaucoma 360 New Horizons Forum in San Francisco on January 29, 2016.
Hosted by Glaucoma Research Foundation, New Horizons provides a unique collaborative exchange on the newest advances in glaucoma.
Glaucoma 360 New Horizons Forum was cofounded in 2012 by Adrienne Graves, PhD, a visual scientist, global industry leader in ophthalmology, and member of the Glaucoma Research Foundation board, with Andrew G. Iwach, MD, director of the Glaucoma Center of San Francisco and chairman of the Foundation’s board of directors. The goal of the Forum is to highlight innovations in glaucoma and unite the various elements needed to bring new ideas into clinical use.
“At New Horizons, we have numerous companies presenting their new technologies and approaches to glaucoma care” said Dr. Iwach. “At the same time, we have venture capitalists looking for their next investment opportunities, and the FDA is there to provide useful tools and advice to the innovators to help them take these new ideas into practice. Each year, there have been significant new developments, and we are anxious to learn more at our 2016 meeting.”
Dr. Graves added, “Over the past four years, the New Horizons Forum has provided a unique venue to get everyone in the glaucoma space together to stimulate and facilitate key discussions and connections. It’s another unique, innovative approach for the Glaucoma Research Foundation to serve as a catalyst in the development of new glaucoma therapies that will help patients preserve their vision.”
Richard A. Lewis, MD (Sacramento Eye Consultants) will deliver the keynote Drs. Henry and Frederick Sutro Memorial Lecture to start the full day of presentations and industry panel discussions featuring innovations in glaucoma drug delivery, pharmaceuticals, and devices, as well as sessions focusing on working with the FDA and securing venture capital funding.
Alan Crandall, MD, a member of Glaucoma 360’s Advisory Board, noted the uniqueness of the New Horizons Forum: “This is the only meeting in glaucoma where you have the interaction with basic science, ophthalmology, industry, investors, and the FDA to learn what is coming, both in the near and distant future, for our patients. It is exciting to learn, sometimes for the first time, what new advances are in development. Glaucoma 360 attracts the who’s who in glaucoma and, from my perspective, is the most exciting meeting of the year.”
Learn more at www.glaucoma360.org
Last reviewed on October 29, 2017
This article appeared in the January 2016 issue of Gleams.Subscribe